Thumbs-up on BMS-Celgene deal ends months of activist outrage by Arlene Weintraub Friday, April 12, 2019 With a shareholder vote in favor of the BMS-Celgene marriage, the combined company will get its chance to prove it's worth the $74 billion price.
Starboard ends BMS proxy war after advisories back Celgene deal by Carly Helfand Monday, April 1, 2019 Recommendations to vote “yes” from proxy advisory firms were enough to end an activist’s efforts to scuttle the BMS-Celgene merger.
Could proxy advisers sway votes against BMS-Celgene merger? by Arlene Weintraub Thursday, March 21, 2019 Proxy advisers will soon weigh in on BMS' $74 billion Celgene buyout, and their verdicts could sway undecided shareholders, analysts say.
Without 'smoking gun,' BMS, Celgene deal will close: analyst by Eric Sagonowsky Tuesday, March 19, 2019 Starboard Value's 197-page presentation against the BMS-Celgene deal lacks a "smoking gun," an analyst wrote. He believes the deal will go through.
Could a Celgene patent dispute tank the BMS deal? by Arlene Weintraub Wednesday, March 13, 2019 Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.
Does Bristol have a plan B if activists scuttle Celgene buy? by Carly Helfand Monday, March 11, 2019 What's Bristol-Myers' Plan B if its Celgene deal falls through? The company won't say whether it has one, much less what it might be.
Activist steps up revolt on BMS-Celgene merger by Arlene Weintraub Wednesday, March 6, 2019 BMS responded to Starboard Value's attempt to scuttle its $74 billion acquisition of Celgene with 46 pages laying out its reasoning for the deal.
Can BMS rebels scuttle its Celgene buy? Analysts do the math by Arlene Weintraub Friday, March 1, 2019 Wellington and other large funds may oppose the BMS-Celgene merger, but the math doesn't add up for a successful thumbs-down vote, analysts report.
Starboard joins BMS' largest investor in condemning Celgene buy by Carly Helfand Wednesday, February 27, 2019 Starboard Value is rallying the troops against BMS' $74 billion Celgene deal, and it has more support than some expected. But will it be enough?
Yes, Starboard has BMS shares—and it wants board seats, too by Carly Helfand Thursday, February 21, 2019 The Bristol-Myers rumors are true. Activist investor Starboard Value has indeed taken a stake in the company—and it’s looking to meddle further.
